1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden Catherine Isitt^{1,2*}, Daniel Sjöholm^{3*}, Maria-Pia Hergens^{2,4}, Fredrik Granath³, Pontus Nauclér^{1,2} 1. Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden 2. Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Sweden 3. Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Karolinska University Hospital, Sweden 4. Department of Communicable Disease Control and Prevention, Stockholm County Council, Stockholm, Sweden * Catherine Isitt and Daniel Sjöholm contributed equally to this manuscript Contact information: Corresponding author Pontus Nauclér pontus.naucler@sll.se, Alternative contact Catherine Isitt catherine.isitt@sll.se Key words: COVID-19, vaccines, SARS-CoV2, cohort study, Long-term-care-facilities Abstract Vaccination against SARS-CoV-2 started in Region Stockholm, Sweden in December 2020 with those in long-term care facilities or receiving home care vaccinated first followed by those aged over 80 years. In this population-based, retrospective cohort study, we performed a Poisson regression to model the expected incidence of infections and deaths which we compared to the observed incidence and compared this to an unvaccinated control group of NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. those aged 18-79 years. The aim of this study was to measure the early impact of the

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

vaccination programme in Region Stockholm. Infections and deaths reduced substantially amongst the first two groups targeted for SARS-CoV-2 vaccination with an estimated total 3112 infections prevented, and 854 deaths prevented in these two groups from 4 weeks after the introduction of vaccination through to 2nd May 2021. Introduction The Swedish COVID-19 vaccination programme prioritises those most at risk of severe disease from SARS-CoV-2 infection first with the aim of protecting those most vulnerable and safeguarding the healthcare system. The programme is divided into four phases: 1) adults living in long-term care facilities (LTCF), adults receiving home care and their household contacts, and healthcare staff working with this population, 2) adults over the age of 65 years as well as adults of any age who receive dialysis or are transplant recipients, with the oldest invited for vaccination first. 3) adults with other risk factors. 4) adults without risk factors over 18 years of age[1]. In Stockholm, vaccination of Phase 1 began on 27th December and vaccination of Phase 2 started on 8th March 2021 with adults >80 years invited for vaccination first[2]. Adults >75 years were invited starting on 29th March 2021[2, 3]. To assess the early impact of the vaccination programme in Stockholm, we performed a population-based, retrospective cohort study to investigate the incidence of PCR-confirmed SARS-CoV-2 as well as deaths within 30 days of a PCR-confirmed SARS-CoV-2 diagnosis, in the cohorts targeted for vaccination compared to a control group not targeted for vaccination. Methods Study population

The Stockholm COVID-19 cohort study collects data from all residents living in Region

Stockholm from 2015 onwards. We extracted data from the VAL database which collates information from more than ten other healthcare related databases in Region Stockholm and which has been previously described[4]. Age, and coding for resident in LTCF and home care were used to define the two groups first targeted for vaccination, those in LTCF/home care and those aged ≥80 years, plus a third group, those aged 18-79 years who were used as a composite unvaccinated control. Linkage to SmiNet, the Public Health Agency of Sweden notifiable infection reporting tool, was performed using unique personal identification numbers that each resident in Sweden has, to extract data on SARS-CoV-2 PCR-positive cases.

The study was approved by the Swedish Ethical Review Authority.

Statistics

Analyses were restricted to 31st August 2020 to 2nd May 2021 in order to encompass the second and third waves of COVID-19 in Stockholm. Data from the first wave were not used given the lack of widely available testing at the start of the pandemic. Three mutually exclusive groups were defined, those in LTCF or receiving home care, those aged 80+ years and a composite control of those aged 18-79 years. The time point set for post-vaccination was 4 weeks after the start of vaccination, to account for the fact that the protective effect of a single dose of vaccine is not immediate and that not all individuals in the group will be vaccinated in the first week. The pre-vaccination incidence rate ratio (IRR) between the three groups were estimated by Poisson regression based on the weekly incidences of cases (and deaths). Due to over dispersion the confidence intervals for the estimated IRRs were adjusted by a standard error inflation factor. The pre-vaccination IRRs (in relation to the composite control group) were used to prognosticate the post-vaccination incidence of infections (and deaths) in absence of vaccination, by multiplying the pre-vaccination IRRs with the observed post-vaccination incidence in the composite control group, using the confidence intervals of the pre-vaccination IRR to show uncertainty in the resulting estimate. Differences between the

prognosticated and observed number of events were used to estimate the number of infections and deaths that may have been prevented up to 2nd May 2021 due to the vaccination programme. Aggregated data on vaccine coverage was grouped by age and residence in LTCF (home care status was not available).

Data was analysed using R version 4.1.0.

Results

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

A total 58,174 people (median age 80 years, IQR 71-87 years) were LTCF residents or receiving home care. In the 80+ group there were 62,306 people (median age 83 years, IQR 81-86 years) whilst in the group aged 18-79 there were 1,748,647 people (median age 44 years, IQR 32-58 years). The proportion of men was lower in both the LTCF/home care group and the 80+ group than in the control group 18–79 year-olds (0.40, 0.43, 0.50 respectively) (Table 1).

Table 1 Demographic data for Region Stockholm taken at end of study period 2021-05-02 divided by group

	LTCF resident/home care	80+	18-79
Total number of persons (N)	58,174	62,306	1,748,647
Median age years (IQR)	80 (71-87)	83 (81-86)	44 (32-58)
Sex (Proportion) Male Female	0.40 0.60	0.43 0.57	0.50 0.50

Infections

The highest number of infections (182,695) were in the control group (18–79 year-olds) (Table 2). More infections were recorded in the LTCF/home care group (6769 total; 5232 prevaccination, 1537 post-vaccination) than in the 80+ group (2464 total; 2276 pre-vaccination, 186 post-vaccination). The IRR for SARS-CoV-2 infection in the LTCF/home care group was 1.70 (95%CI 1.54-1.88) pre-vaccination and 0.59 (0.49-0.71) post-vaccination compared to the composite control, higher than for the 80+ group which were 0.38 (0.33-0.44) pre-vaccination and 0.17 (0.09-0.27) post-vaccination (Table 2, Figure 1A). Weekly observed versus expected incidences of infection per 100,000 days at risk are presented in Figure 1A. The estimated number of infections prevented by vaccination was 2873 (2441-3337) for the LTCF/home care group and 239 (178-306) for the 80+ group (Table 2).

Table 2 Summary of SARS-CoV2 infections between 2020-08-31 and 2021-05-02 in Region Stockholm

	LTCF resident/home care (n=58,174)	80+ (n= 62,306)	18-79 (n=1,748,647)
Total infections during study period (N)*	6769	2462	182, 695
Infections after vaccination	1537	186	N/A
Sum expected infections after vaccination	4410 (3978-4874)	425 (364-492)	N/A
Sum observed infection after vaccination	1537	186	N/A
Estimated prevented infections (95% CI)	2873 (2441-3337)	239 (178-306)	N/A
Infection incidence rate ratio pre-vaccination (95% CI)	1.70 (1.54-1.88)	0.38 (0.33-0.44)	Reference
Infection incidence rate ratio post-vaccination (95% CI)	0.59 (0.49-0.71)	0.17 (0.09-0.27)	Reference

^{*}Summary infections between 2020-08-31 and 2021-05-02

Mortality

More deaths within 30 days of a positive SARS-CoV2 PCR test were recorded in the LTCF/home care groups than in the 80+ group during the study period (1218 vs 244) (Table

3). In both groups the majority of deaths occurred prior to the start of vaccination; in the LTCF/home care group there were 978 pre-vaccination and 240 post-vaccination whereas in the 80+ group there were 224 pre-vaccination and 20 post-vaccination. 348 deaths were recorded in the 18-79 group. The IRR for death within 30 days of a positive SARS-CoV2 PCR test decreased from 179 (95%CI 146-221) pre-vaccination to 45 (35-59) post-vaccination for the LTCF/home care group and from 20 (16-26) pre-vaccination to 9 (5-18) post-vaccination for the 80+ group, compared to the composite control (Figure 1B). The estimated number of deaths prevented after vaccination was 808 (95%CI 615-1053) for the LTCF/home care group and 46 (32-64) for the 80+ group (Table 3, Figure 1B). Weekly observed versus expected incidence for deaths are presented in Figure 1B.

Table 3 Summary of deaths within 30 days of a positive SARS-CoV2 PCR test between

2020-08-31 and 2021-05-02 in Region Stockholm


	LTCF resident/homecare (n=58,174)	80+ (n= 62,306)	18-79 (n=1,748,647)
Total deaths during study period (N)	1218	244	348
Deaths after vaccination	240	20	N/A
Death incidence rate ratio pre-vaccination (95% CI)	179 (146-221)	20 (16-26)	Reference
Death incidence rate ratio post-vaccination (95% CI)	45 (35-59)	9 (5-18)	Reference
Sum expected deaths after vaccination (95% CI)	1048 (855-1293)	66 (52-84)	N/A
Sum observed deaths	240	20	N/A
Estimated prevented deaths (95% CI)	808 (615-1053)	46 (32-64)	N/A

Vaccine coverage and choice of vaccines in Stockholm

Figures 1C and 1D show the vaccine coverage with doses 1 and 2 stratified by LTCF, age

80+ and ages 18-79. In both the LTCF and 80+ group, at least 80% of the group had received a first dose by 4 weeks after the start of vaccination of the group. The vaccine coverage data was based on LTCF and age, since data for those receiving home care was not available by vaccine status.

Figure 1. A. Weekly incidence of SARS-CoV-2 infection per 100,000 days at risk by group observed and estimated in the absence of vaccination (LTCF/home care, 80+, 18-79) **B.** Weekly deceased per 100,000 days at risk by group observed and estimated in the absence of vaccination (LTCF/home care, 80+, 18-79) **C.** Vaccine coverage with dose 1 by group (LTCF only, 80+, 18-79), **D.** Vaccine coverage with dose 2 by group (LTCF only, 80+, 18-79)



Discussion

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

Our data suggests that vaccination of the LTCF/home care and 80+ groups succeeded in preventing a third wave in these groups of the same magnitude as the control group. Since the start of the vaccination programme there has been no national lock-down or increase in restrictions to visiting friends and relative in LTCF and as such the effect of prevention of infections and deaths is likely to be due to vaccination rather than to new social distancing measures alone[5]. The IRR for infections and deaths was much lower in the 80+ group compared to the LTCF/home care group even prior to vaccination, which is likely to be an effect of the Swedish recommendations, that is, that those over 70 years take extra precautions to avoid social contact with others outside their own household[6]. Those receiving home care who have regular visits by healthcare professionals and those living in LTCF have not been able to isolate to the same extent and have been much more vulnerable to the spread of infection[7]. A combination of EU approved vaccines has been used since the start of the programme. Use of the Pfizer-BioNTech mRNA vaccine started on 27th December 2020 followed by the Moderna mRNA vaccine after it received EMA approval on 6th January 2021[8]. Astra-Zeneca's COVID-19 vaccine received EMA approval on 29th January 2021[8] although vaccination of those over 65 years with Astra-Zeneca's vaccine only started on 4th March due to initial concerns about effectiveness in older adults[9]. Vaccination with Astra-Zeneca's vaccine was paused between 16th and 25th March whilst reports of links with a rare blood clotting disorder were investigated[3]. Since 25th March, vaccination with Astra-Zenecas vaccine has been resumed amongst those over 65[3, 10, 11]. It is likely therefore that the majority of those vaccinated in the LTCF/home care and 80+ groups received mRNA vaccines. The effect observed is a combination of protection from a single dose and two doses. High vaccine coverage by 4 weeks post-vaccination was achieved in both of the first groups

targeted for vaccination. Timing of the second dose of vaccinations has varied in Stockholm

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

based on which vaccine is given and time point during the vaccination programme. Currently the mRNA vaccines are given with a 3-7 week dosing interval and Astra-Zeneca's vaccine with a 6-12 week interval[12]. This study was limited to programmatic effect in that we were unable to link individual level vaccine data as has recently been done in Israel[13] however little has yet been published on the impact of programmes using heterologous vaccines such as this one which is one of the studies strengths. A recent internal report from Public Health England estimates 10,400 deaths have been prevented in England in the first 4 months of their COVID-19 vaccination programme using non-individual level data[14]. The advantage of before and after studies is that they take into account both the direct and indirect effects of vaccination. An additional limitation in our study is that vaccine coverage data was based on LTCF and age, since data for those receiving home care was not available whereas incidence of infections and deaths were calculated for the combined group (LTCF/home care). Some of the reduction observed in the LTCF/home care group is likely due to indirect effects of vaccination of healthcare workers. Reductions in observed vs. expected infections in the 80+ group started before vaccination indicating that the assumptions about symmetrical infection incidence ratio during the second and third wave might not be fully accurate. The overall trend, however, following initiation of vaccination is highly encouraging. In conclusion, the programmatic early effects of vaccination in two of the most vulnerable groups are both reduced SARS-CoV-2 infections and deaths.

Authorship

213

214

219

220

221

- 215 All authors have seen and approved the manuscript and contributed significantly to the work.
- 216 PN devised the study, CI wrote the manuscript and contributed to the analysis, DS
- 217 performed the main analysis, FG assisted with statistical analyses and MPH analysed and
- 218 provided the vaccination data.

References

- 222 [1] Folkhälsomydigheten, Nationell plan för vaccination mot covid-19 (delrapportering
- 223 3) 2021.
- 224 https://www.folkhalsomyndigheten.se/contentassets/43a1e203f7344a399367b816e2
- 225 <u>c7144c/nationell-plan-vaccination-covid-19-delrapport-3.pdf.</u> (Accessed 4th July 2021).
- 226 [2] R. Stockholm, 17 juni: Dagsläge covid-19, 2021.
- 227 https://www.sll.se/verksamhet/halsa-och-vard/nyheter-lagesrapporter-covid-
- 228 19/2021/06/17-juni-dagslage-covid-19/. (Accessed 19th June 2021).
- 229 [3] Folkhälsomydigheten, Information om vaccination med Astra Zenecas vaccin till
- 230 personer som är 65 år och äldre, 2021.
- https://www.folkhalsomyndigheten.se/smittskydd-beredskap/utbrott/aktuella-231
- 232 utbrott/covid-19/vaccination-mot-covid-19/om-vaccinerna-mot-covid-
- 233 19/information-om-fortsatt-vaccination-av-astra-zenecas-vaccin-till-personer-som-ar-
- 234 65-ar-och-aldre/. (Accessed 4th June 2021).
- 235 [4] T. Forslund, A.C. Carlsson, G. Ljunggren, J. Arnlov, C. Wachtler, Fam Pract 38(2)
- 236 (2021) 132-140.
- [5] Folkhälsomydigheten, Tillfälliga lokala besöksförbud på äldreboenden upphör, 237
- 238 2021. https://www.folkhalsomyndigheten.se/smittskydd-beredskap/utbrott/aktuella-
- 239 utbrott/covid-19/information-till-varden/personal-inom-aldreomsorg/lokala-
- besoksforbud-pa-aldreboenden/. (Accessed 1st July 2021). 240
- 241 [6] Folkhälsomydigheten, Folkhälsomyndighetens föreskrifter och allmänna råd om
- allas ansvar att förhindra smitta av covid-19 m.m., 2020. 242
- 243 https://www.folkhalsomyndigheten.se/contentassets/a1350246356042fb9ff3c515129
- e8baf/hslf-fs-2020-12-allmanna-rad-om-allas-ansvar-covid-19-tf.pdf. (Accessed 4th 244
- 245 July 2021).
- 246 [7] S. Baral, R. Chandler, R.G. Prieto, S. Gupta, S. Mishra, M. Kulldorff, Ann Epidemiol 54
- 247 (2021) 21-26.
- 248 [8] Läkemedelsverket, Coronavaccin, vaccin mot coronaviruset (covid-19), 2021.
- 249 https://www.lakemedelsverket.se/sv/coronavirus/coronavaccin. (Accessed 4th July
- 250 2021).
- 251 [9] Folkhälsomydigheten, Samtliga godkända vacciner mot covid-19 skyddar mot
- 252 sjukdom, 2021. https://www.folkhalsomyndigheten.se/nyheter-och-
- 253 press/nyhetsarkiv/2021/februari/samtliga-godkanda-vacciner-mot-covid-19-skyddar-
- 254 mot-sjukdom/. (Accessed 4th July 2021).

perpetuity.
All rights reserved. No reuse allowed without permission.

[10] Folkhälsomydigheten, Om vaccinerna mot covid-19, 2021. 255 https://www.folkhalsomvndigheten.se/smittskydd-beredskap/utbrott/aktuella-256 utbrott/covid-19/vaccination-mot-covid-19/om-vaccinerna-mot-covid-19/om-257 258 vaccinerna/. (Accessed 4th June 2021). [11] Folkhälsomydigheten, Rekommendation om åldersgräns på 65 år för AstraZenecas 259 vaccin kvarstår, 2021, https://www.folkhalsomvndigheten.se/nvheter-och-260 press/nyhetsarkiv/2021/april/rekommendation-om-aldersgrans-pa-65-ar-for-261 262 astrazenecas-vaccin-kvarstar/. (Accessed 4th June 2021). 263 [12] Folkhälsomvdigheten. Om vaccinerna mot covid-19. 2021. 264 https://www.folkhalsomvndigheten.se/smittskydd-beredskap/utbrott/aktuellautbrott/covid-19/vaccination-mot-covid-19/om-vaccinerna-mot-covid-19/om-265 266 vaccinerna/. (Accessed 4th July 2021). 267 [13] E.J. Haas, F.J. Angulo, J.M. McLaughlin, E. Anis, S.R. Singer, F. Khan, N. Brooks, M. 268 Smaja, G. Mircus, K. Pan, J. Southern, D.L. Swerdlow, L. Jodar, Y. Levy, S. Alroy-Preis, 269 Lancet 397(10287) (2021) 1819-1829. 270 [14] I.S. Nick Andrews, Sharif Ismael, Laura Coughlan, Hester Allen, Mary Ramsay, Jamie Lopez Bernal, Impact of COVID-19 vaccines on mortality in England: December 2020 to 271 272 March 2021, 2021. 273 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach 274 ment data/file/977249/PHE COVID-19 vaccine impact on mortality March.pdf. 275 (Accessed 4th July 2021). 276 277 278 279 280 281 282 283 284